Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Advances in Microarray Technology

's Biography



, ,

Larry Gold is the founder, Chairman of the Board, and Chief Executive Officer of SomaLogic. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases. During nearly 10 years at NeXstar, Dr. Gold held numerous executive positions including Chairman of the Board, Executive VP of R&D, and Chief Science Officer. Before forming NeXagen, he also co-founded and served as co-Director of Research at Synergen, Inc., a pioneering biotechnology company later acquired by Amgen, Inc. Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder (CU). While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992. During his prestigious career, Dr. Gold has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology. In addition, Dr. Gold has been a member of the American Academy of Arts and Sciences since 1993 and the National Academy of Sciences since 1995. Dr. Gold also serves on the board of directors of Complegen, MicroPhage, and Plato BioPharma

  Image

From High Content Proteomic Arrays to Diagnostic Tests

Wednesday, 28 March 2012 at 16:30

Add to Calendar ▼2012-03-28 16:30:002012-03-28 17:30:00Europe/LondonFrom High Content Proteomic Arrays to Diagnostic TestsAdvances in Microarray Technology in Edinburgh, ScotlandEdinburgh, ScotlandSELECTBIOenquiries@selectbiosciences.com

SomaLogic has developed a platform in which more than 1,000 different  human proteins are quantified simultaneously.  Novel biomarkers have been discovered for several cancers, cardiovascular disease, and other conditions.  The seamless path from biomarker discovery to useful diagnostics will be described.


Add to Calendar ▼2012-03-28 00:00:002012-03-29 00:00:00Europe/LondonAdvances in Microarray TechnologyAdvances in Microarray Technology in Edinburgh, ScotlandEdinburgh, ScotlandSELECTBIOenquiries@selectbiosciences.com